恩替卡韦对慢性乙型肝炎外周血Th9/Treg的影响

目的 观察恩替卡韦抗病毒治疗对慢性乙型肝炎外周血辅助性T细胞（helper T cells，Th）9/调节性T细胞（regulatory T cells，Treg）的影响。方法 收集杭州市第三人民医院2019年1月至2020年1月符合抗病毒治疗指征的慢性乙型肝炎患者40例，予恩替卡韦（0.5mg/d）抗病毒治疗，观察时间24周，治疗前后分别检测血清肝功能、乙型肝炎病毒脱氧核糖核酸（hepatitis B virus deoxyribonucleic acid，HBV-DNA）、外周血Th9细胞频数、Treg细胞频数等指标，观察抗病毒疗效与外周血Th9/Treg的关系。结果 恩替卡韦治疗前后丙氨酸氨基转移酶（alanine transaminase，ALT）、HBV-DNA、Th9、Treg、Th9/Treg比较，差异均有统计学意义（P<0.05）；治疗24周后ALT复常33例，未复常7例，两组ALT、Th9、Treg、Th9/Treg比较，差异均有统计学意义（P<0.05）；治疗24周后HBV-DNA转阴34例，未转阴6例，两组HBV-DNA、Treg、Th9/Treg比较，差异均有统计学意义（P<0.05）。结论 恩替卡韦抗病毒治疗可降低外周血Th9、Treg水平，Th9/Treg比值降低，与疗效相关。

Effects of entecavir on peripheral blood Th9/Treg in patients with chronic hepatitis B

Objective To observe the effect of entecavir antiviral therapy on peripheral blood Th9/Treg of chronic hepatitis B. Methods A total of 40 patients with chronic hepatitis B conforming to antiviral therapy indications were collected from Hangzhou Third People''s Hospital from January 2019 to January 2020. They were treated with entecavir (0.5mg/d) for 24 weeks. Serum liver function, HBV-DNA, peripheral blood Th9 cell frequency, Treg cell frequency and other indicators were detected before and after treatment, and the relationship between antiviral efficacy and peripheral blood Th9/Treg was observed. Results There were statistically significant differences in ALT, HBV-DNA, Th9, Treg and Th9/Treg before and after entecavir treatment (P<0.05). After 24 weeks of treatment, 33 cases returned to normal ALT, and 7 cases did not return to normal ALT. There were statistically significant differences in ALT, Th9, Treg and Th9/Treg between the two groups (P<0.05). After 24 weeks of treatment, 34 cases turned negative for HBV-DNA, and 6 cases did not. There were statistically significant differences in HBV-DNA, Th9, Treg, and Th9/Treg between the two groups (P<0.05). Conclusion Entecavir antiviral treatment can reduce the levels of Th9 and Treg in peripheral blood, and the Th9/Treg ratio decreases, which is related to the efficacy.